Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that Philip Raskin, MD, of The University of Texas Southwestern Medical Center in Dallas, Texas, made a presentation in respect of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, at The Latin America Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy) held in Buenos Aires, Argentina, March 11-14, 2010 (www.comtecmed.com/Codhy/argentina).
Dr. Raskin's presentation was entitled "The Buccal Delivery of Insulin and its Effect in Type 1 Diabetes". The presentation offered conclusions that Generex Oral-lyn™ is as effective as regular insulin therapy in patients with Type 1 diabetes taking twice daily NPH basal insulin and it is well tolerated and safe.
"We are pleased with the continuing positive reception that Generex Oral-lyn™ is receiving in the international scientific community," said Anna Gluskin, the Company's President & Chief Executive Officer. "We believe that our product resembles the body's natural insulin response effectively and has the flexibility that allows patients to fine-tune their insulin treatment regimens for optimum therapeutic results."
The objective of the CODHy congress is to promote excellence in the fields of diabetes, obesity, and hypertension.
Can probiotics improve insulin resistance in women with PCOS?